Kunins Jeffrey C

CPO & CTO Kunins sells 1,797 shares for $968,992.46; 5 prior AXON sales all well-timed 90d, stock down 25.6% in 90 days

Jeffrey C. Kunins (CPO & CTO) executed 5 separate sales totaling 1,797 shares for $968,992.46 on 2025-12-02, representing a 2.1% reduction in his 83.5K post-transaction holdings. His prior 5 trades at AXON (all on 2025-08-14) showed a consistent pattern: positive 30-day returns (ranging from +0.4% to +1.2%) followed by sharp 90-day declines (ranging from -23.8% to -24.4%), with all 5 well-timed at the 90-day horizon. The stock has declined 25.6% over the past 90 days from these latest sales, suggesting a continuation of the historical pattern. While the company reports strong fundamental growth (revenue $710.6M, +33.2% annual growth), the elevated valuation (P/E 166.73) and current price position 37.6% below the 52-week high provide context for the sustained sell activity by a senior executive.

AXON CPO Jeffrey Kunins sold 7,891 shares for $5,919,010.66 in 8 separate sales on 2025-08-14, reducing holdings 5.2%

Jeffrey Kunins, CPO & CTO of Axon Enterprise, executed 8 separate sales on 2025-08-14 totaling 7,891 shares (7.9K shares) for $5,919,010.66 (blended average $750.10), reducing his holdings from 152,429 to 144,538 shares. His cross-ticker track record shows a 100.00% well-timed rate across 20 prior sells with an average 90-day return of -15.8%, and his 5 prior sales at AXON were uniformly well-timed, with 5 of 5 prior sells generating negative 90-day returns ranging from -2.4% to -14.0%. Current price is $754.24, representing a -13.4% discount from the 52-week high of $870.97. This large, multi-tranche divestiture by a technology executive with a documented pattern of well-timed exits at this specific ticker merits closer evaluation of forward guidance and near-term business momentum.

CPO & CTO Jeffrey C Kunins sells 1,035 shares at $622.68–$626.17 on 2024-12-23 for $646,328.84.

Jeffrey C Kunins, CPO & CTO of Axon Enterprise, executed 4 separate sales totaling 1,035 shares for $646,328.84 on 2024-12-23, reducing his holdings by 0.8% to 124,243 shares post-transaction. The blended average price was $624.47, just above the current price of $623.80, and within the 52-week range. Kunins has a prior track record across all tickers showing 20 prior sells with an average 30-day return of +6.5%, though his same-ticker history at AXON shows 5 prior sales on 2024-12-17 with outcomes not yet measurable. This sale occurred in a context of strong near-term momentum (90-day change: +57.8%) and elevated valuation (P/E: 159.13), following a recently reported quarterly revenue of $544,274,000.00 with net income of $67,025,000.00 and annual growth of +31.4%.

CPO & CTO Kunins sells 1,370 shares at avg $639.14 for $875.6K; retains 126.0K shares post-sale

Jeffrey C. Kunins, CPO & CTO, executed 7 separate sales on 2024-12-17 totaling 1,370 shares for $875,622.60 at prices ranging from $635.24 to $644.91, representing a blended average of $639.14. This sale reduced his holdings by 1.1% from 127,320 to 125,950 shares, leaving him with a substantial stake of 126.0K shares. The transaction occurred when AXON stock was trading near its 52-week high of $689.78 (current price $635.76 is -7.8% from that peak), and the company reported strong fundamentals including annual revenue growth of +31.4% and a market cap of $48.5B. His cross-ticker track record shows 20 prior sells with an average 30-day return of +6.0%, though his same-ticker prior sales at AXON (5 recent trades in early December) lack measurable outcomes yet.

CPO & CTO Jeffrey Kunins sells 2,637 shares at $642.92–$673.00 for $1,730,769.10; holds 128.2K shares post-sale.

Kunins executed 11 separate sales totaling 2,637 shares for $1,730,769.10 on 2024-12-03 and 2024-12-04 at prices ranging from $642.92 to $673.00, reducing his holdings by 2.0% to 128,209 shares. The current price of $687.39 is at the 52-week high, and AXON has rallied +59.3% over 30 days and +93.7% over 90 days, reflecting strong recent momentum. Kunins' cross-ticker track record shows a 90d well-timed rate of 0.00% across 20 prior sells, indicating his sales have not historically preceded price declines; his same-ticker AXON history consists of 5 prior sells on 2024-11-13 with no measurable outcomes yet. The magnitude of the sale ($1.7M) against total market cap ($52.4B) and his remaining stake (128.2K shares) suggests a modest portfolio adjustment rather than a major exit, warranting observation of whether this activity clusters with broader insider behavior.

CPO Jeffrey Kunins sells 43,668 shares at $601.58 avg for $26.3M, reducing stake by 24.8%

Kunins executed 13 separate sales totaling 43,668 shares for $26,269,686.30 over two trading days (Nov 12-13), reducing his holdings from 176,228 to 132,560 shares—a 24.8% reduction in his position. The blended average sale price of $601.58 sits near the current price of $604.56 and only 1.9% below the 52-week high of $616.14, indicating the sales occurred at elevated valuation levels during a period of strong momentum (+39.3% over 30 days, +61.8% over 90 days). While his prior five trades at AXON (all Sep 2024 sells) showed positive 30-day returns ranging 17.6%–19.1%, his cross-ticker track record reveals a 0.00% well-timed rate on 20 prior sells, with an average 90-day return of +24.2%, meaning his historical sales have been poorly timed relative to subsequent gains. The company carries a high P/E of 154.22 on strong fundamentals (31.4% annual revenue growth, $544.3M latest quarterly revenue), but the significance of the sale size and timing against his own historical execution pattern warrants attention.

CPO Jeffrey Kunins sells 8,182 shares of AXON at blended $364.86; 30-day returns negative across prior AXON sales.

Kunins, the Chief Product Officer & CTO, executed 5 separate sales totaling 8,182 shares for $2,985,294.10 on 2024-09-09 at prices ranging from $362.93 to $367.44. The transaction reduced his holdings by 4.4%, leaving 176,228 shares post-sale. His prior 5 trades at AXON (all sells in May and December 2023) show a consistent pattern: each sale was followed by a 30-day decline ranging from -1.1% to -10.2%, though 90-day returns turned positive in each case. The current stock price of $359.35 sits 4.2% below the 52-week high of $375.10, and AXON trades at a P/E of 93.34 against strong fundamentals (31.4% annual revenue growth, $504.1M quarterly revenue). The immediate market context shows a -1.6% 30-day decline and +21.5% 90-day gain, but his historical same-ticker record at AXON shows 0 of 5 prior sells were well-timed at the 90-day mark.